Tags

Type your tag names separated by a space and hit enter

Amyloid imaging of Lewy body-associated disorders.
Mov Disord 2010; 25(15):2516-23MD

Abstract

Clinicopathologic studies of Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB) commonly reveal abnormal β-amyloid deposition in addition to diffuse Lewy bodies (α-synuclein aggregates), but the relationship among these neuropathologic features and the development of dementia in these disorders remains uncertain. The purpose of this study was to determine whether amyloid-β deposition detected by PET imaging with Pittsburgh Compound B (PIB) distinguishes clinical subtypes of Lewy body-associated disorders. Nine healthy controls, 8 PD with no cognitive impairment, 9 PD with mild cognitive impairment, 6 DLB, and 15 PDD patients underwent [(11)C]-PIB positron emission tomography imaging, clinical examination, and cognitive testing. The binding potential (BP) of PIB for predefined regions and the mean cortical BP (MCBP) were calculated for each participant. Annual longitudinal follow-up and postmortem examinations were performed on a subset of participants. Regional PIB BPs and the proportion of individuals with abnormally elevated MCBP were not significantly different across participant groups. Elevated PIB binding was associated with worse global cognitive impairment in participants with Lewy body disorders but was not associated with any other clinical or neuropsychological features, including earlier onset or faster rate of progression of cognitive impairment. These results suggest that the presence of fibrillar amyloid-β does not distinguish between clinical subtypes of Lewy body-associated disorders, although larger numbers are needed to more definitively rule out this association. Amyloid-β may modify the severity of global cognitive impairment in individuals with Lewy body-associated dementia.

Authors+Show Affiliations

Department of Neurology, Washington University School of Medicine, St Louis, MO, USA. erfoster@wustl.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20922808

Citation

Foster, Erin R., et al. "Amyloid Imaging of Lewy Body-associated Disorders." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 25, no. 15, 2010, pp. 2516-23.
Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord. 2010;25(15):2516-23.
Foster, E. R., Campbell, M. C., Burack, M. A., Hartlein, J., Flores, H. P., Cairns, N. J., ... Perlmutter, J. S. (2010). Amyloid imaging of Lewy body-associated disorders. Movement Disorders : Official Journal of the Movement Disorder Society, 25(15), pp. 2516-23. doi:10.1002/mds.23393.
Foster ER, et al. Amyloid Imaging of Lewy Body-associated Disorders. Mov Disord. 2010 Nov 15;25(15):2516-23. PubMed PMID: 20922808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amyloid imaging of Lewy body-associated disorders. AU - Foster,Erin R, AU - Campbell,Meghan C, AU - Burack,Michelle A, AU - Hartlein,Johanna, AU - Flores,Hubert P, AU - Cairns,Nigel J, AU - Hershey,Tamara, AU - Perlmutter,Joel S, PY - 2010/10/6/entrez PY - 2010/10/6/pubmed PY - 2011/2/26/medline SP - 2516 EP - 23 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 25 IS - 15 N2 - Clinicopathologic studies of Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB) commonly reveal abnormal β-amyloid deposition in addition to diffuse Lewy bodies (α-synuclein aggregates), but the relationship among these neuropathologic features and the development of dementia in these disorders remains uncertain. The purpose of this study was to determine whether amyloid-β deposition detected by PET imaging with Pittsburgh Compound B (PIB) distinguishes clinical subtypes of Lewy body-associated disorders. Nine healthy controls, 8 PD with no cognitive impairment, 9 PD with mild cognitive impairment, 6 DLB, and 15 PDD patients underwent [(11)C]-PIB positron emission tomography imaging, clinical examination, and cognitive testing. The binding potential (BP) of PIB for predefined regions and the mean cortical BP (MCBP) were calculated for each participant. Annual longitudinal follow-up and postmortem examinations were performed on a subset of participants. Regional PIB BPs and the proportion of individuals with abnormally elevated MCBP were not significantly different across participant groups. Elevated PIB binding was associated with worse global cognitive impairment in participants with Lewy body disorders but was not associated with any other clinical or neuropsychological features, including earlier onset or faster rate of progression of cognitive impairment. These results suggest that the presence of fibrillar amyloid-β does not distinguish between clinical subtypes of Lewy body-associated disorders, although larger numbers are needed to more definitively rule out this association. Amyloid-β may modify the severity of global cognitive impairment in individuals with Lewy body-associated dementia. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/20922808/Amyloid_imaging_of_Lewy_body_associated_disorders_ L2 - https://doi.org/10.1002/mds.23393 DB - PRIME DP - Unbound Medicine ER -